By Phil Boeyen, ShareChat Business News Editor
|
Friday 15th February 2002 |
Text too small? |
The company says Pharmabroker Sales will manage the New Zealand sales and distribution of its new lozenges, which contain a strain of beneficial bacteria called Streptococcus salivarius K12.
"This appointment is a significant milestone for the company, enabling the first of a range of Blis products to be released by the company in advance of the coming winter season," says chief executive Kelvin Moffatt.
Blis is pointing out that the bacteria in the lozenges is not genetically engineered but occur naturally in a small percentage of the population.
"These 'good' bacteria have been shown to assist in maintaining throat health by supporting the throat's natural defences against undesirable bacteria," says Mr Moffat.
"Using BLIS K12 Throat Guard within 24 hours of completing a course of prescribed antibiotics can also help ensure that the beneficial bacteria, as opposed to undesirable bacteria, repopulate the mouth and throat."
The company claims a course of twelve lozenges will help support the throat's natural defences against undesirable bacteria for up to one month.
"The appointment of Pharmabroker provides national coverage of retail pharmacy and medical channels, as well as securing the assistance of a specialist who is recognised for its expertise in building brands."
Blis Technologies was formed to commercialise bacteriocin-like inhibitory substances and has a number of other products in the pipeline including ones for control of dental caries and for the prevention and treatment of ear infections, bovine mastitis, and skin infections.
No comments yet
BLIS Technologies announces a net deficit of $1,856k for the March 2013 financial year
Blis share price spike
Blis to clean up share register, buying small parcels
Blis K12 probiotic to get ruff ruff test in dogs
BLIS Technology forecasts wider 2013 loss, seeks to raise capital
